We are proud to have the opportunity to work in collaboration together with BioArctic in this study we have been performing IHC binding of Lecanemab in Down syndrome and Alzheimer's disease
This study shows for or the first time, Lecanemab (an antibody with higher avidity for toxic Aβ aggregates), binding to Aβ protofibrils and plaques in people with Down syndrome is demonstrated
Lecanemab currently in phase 3 clinical studies and has shown to reduce brain amyloid levels in the brain of Alzheimer's disease patients
